Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycophenolate mofetil--clinical and experimental experience

J D Pirsch1, H W Sollinger

  • 1Department of Medicine, University of Wisconsin Medical School, Madison, USA.

Therapeutic Drug Monitoring
|August 1, 1996
PubMed
Summary

Mycophenolate mofetil (MMF) effectively prevents renal allograft rejection by inhibiting guanine nucleotide synthesis in lymphocytes. This immunosuppressant significantly reduces acute rejection rates in kidney transplant patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of ureteral stricture and treatment choice on long-term graft survival in kidney transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2018
Same author

Acute cellular and antibody-mediated rejection of the pancreas allograft: incidence, risk factors and outcomes.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2013
Same author

Is there any role for antithymocyte induction in renal transplantation?

Transplantation proceedings·2010
Same author

FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study.

Clinical transplantation·2009
Same author

Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2009
Same author

Stability of alemtuzumab for low-dose induction and test doses.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2009

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Mycophenolate mofetil (MMF) is an immunosuppressant drug.
  • It is the morpholinoethyl ester of mycophenolic acid (MPA).
  • MMF is a selective, reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH).

Purpose of the Study:

  • To evaluate the efficacy of MMF in preventing renal allograft rejection.
  • To understand the mechanism of action of MMF and MPA.

Main Methods:

  • Clinical studies involving human kidney transplant recipients.
  • Comparison of MMF with azathioprine or placebo control.
  • Analysis of drug conversion from MMF to MPA and its pharmacologic activity.

Main Results:

Related Experiment Videos

  • MMF demonstrated significant efficacy in preventing renal allograft rejection.
  • A major clinical study showed a 50% reduction in acute rejection incidence compared to control groups.
  • Primary side effects included leukopenia, gastrointestinal issues, and cytomegalovirus disease.

Conclusions:

  • MMF represents a significant advancement in immunosuppression for renal transplant recipients.
  • The drug's efficacy is linked to its inhibition of IMPDH, particularly in lymphocytes.
  • Ongoing research is exploring MMF's use in other solid organ transplantations.